晚期癌性贫血患者血清促红细胞生成素和网织红细胞参数的分析

目的研究对晚期癌性贫血患者促红细胞生成素（EPO）的水平及其对患者贫血症状作用的临床意义。方法收集多种晚期癌性贫血患者血清，应用放射免疫法检测EPO水平。以正常人、非癌性贫血患者作为对照。同时检测各组血红蛋白（Hb）、网织红细胞参数包括网织红细胞数（RET）、网织红细胞生成指数（RPI）。分析各组EPO水平差异及其与Hb、网织红细胞参数的相关性。结果晚期癌性贫血组患者血清EPO为（2．69±1．30）μg／L，RET（2．78±1．06）％，RPI1．44±0．32；正常对照组患者血清EPO为（1．59±0．69）μg／t，PET（1．17±0．35）％，RPI0．98±0．25；非癌性贫血组患者血清EPO为（2．78±1．53）pg／L，PET（5．46±2．12）％，RPI2．34±0．35；癌性贫血组患者与正常对照组患者比较，其血清EPO、Hb、PET、RPI值均存在显著差异（P〈0．01）；癌性贫血组患者与非癌性贫血组患者比较，RET、RPI检测结果存在显著差异（P〈0．01）；癌性贫血组和非癌性贫血组患者EPO和RET、RPI值的相关系数存在显著差异（P〈0．01）。结论晚期癌性贫血患者血清EPO水平反应性增高，但机体对EPO反应性减弱。

Detection and Clinical Analysis of Erythropoitin and Eeticnlocyte in Patients with Advanced Cancer-Related Anemia

Objective To etect erythropoitin in patients with advanced cancer-related anemia and analyse the clinical signification. Methods Blood of patients with advanced cancer-related anemia were collected and erythropoitin was detected by radioimmuno-assay, hemoglobin（Hb） and reticulocyte（RET）, reticulocyte production index（RPI） were detected also. Normal and patients with non-cancer-related anemia were employed as control groups. Results The erythropoitin of patients with advanced cancer-related anemia was （2.69± 1.30）/.tg/L, hemoglobin（89.8±10.0） g/L, reticulocyte （2.78± 1.06）%, RPI 1.44± 0.32. Erythropoitin was （1.59± 0.69）μg/L, hemoglobin（136.1± 11.3） g/L, reticulocyte （1.17± 0.35）%, RPI 0.98± 0.25 in normal controls. Erythropoitin was （2.82± 1.16）μg/L, hemoglobin（90.2± 11.5） g/L, reticulocyte （5.7 ± 2.7）% , RPI 2,34 ± 0.35 in controls of non-cancer-related anemia. Compared with normal controls, the erythropoitin, hemoglobin and reticulocyte, RPI of patients with advanced cancer-related anemia were significant difference （P〈0.01）. The reticulocyte and RPI were significant different compared the patients with advanced cancer-related anemia with the patients with non-cancer-related anemia （P 〈0.01）. The coefficient of correlation between erythropoitin and reticulocyte, RPI were significant different in the patients with advanced cancer-related anemia compared with the patients with non-cancer-related anemia （P 〈0.01）. Conclusion The erythropoitin of patients with advanced cancer-related anemia increased responsively but the reactivity of erythropoitin decreased.